Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis

Trial Profile

Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Everolimus (Primary) ; Sirolimus (Primary) ; Zotarolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms Z-SEA-SIDE
  • Most Recent Events

    • 20 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top